Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.

Deregulation of c-Met receptor tyrosine kinase activity leads to tumorigenesis and metastasis in animal models. More importantly, the identification of activating mutations in c-Met, as well as MET gene amplification in human cancers, points to c-Met as an important target for cancer therapy. We have previously described two classes of c-Met kinase inhibitors (class I and class II) that differ in their binding modes and selectivity profiles. The class II inhibitors tend to have activities on multiple kinases. Knowledge of the binding mode of these molecules in the c-Met protein led to the design and evaluation of several new class II c-Met inhibitors that utilize various 5-membered cyclic carboxamides to conformationally restrain key pharmacophoric groups within the molecule. These investigations resulted in the identification of a potent and novel class of pyrazolone c-Met inhibitors with good in vivo activity.

[1]  S. Bellon,et al.  c-Met inhibitors with different binding modes: Two is better than one , 2008, Cell cycle.

[2]  J. Fargnoli,et al.  Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. , 2009, Journal of medicinal chemistry.

[3]  Toshiyuki Shimizu,et al.  Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. , 2005, Journal of medicinal chemistry.

[4]  Stephen K Burley,et al.  SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo , 2009, Molecular Cancer Therapeutics.

[5]  Michael B. Smith,et al.  A Mild and Facile Route to ω-Amino Esters , 1988 .

[6]  D. Whittington,et al.  Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series. , 2012, Journal of medicinal chemistry.

[7]  M. Robert,et al.  N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[8]  Daniel Rauh,et al.  A new screening assay for allosteric inhibitors of cSrc. , 2009, Nature chemical biology.

[9]  Yuan Cheng,et al.  Design, synthesis, and biological evaluation of potent c-Met inhibitors. , 2008, Journal of medicinal chemistry.

[10]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[11]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[12]  W. Childers,et al.  Oxidation of α,β-un saturated aldehydes , 1981 .

[13]  J. Fargnoli,et al.  Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities. , 2008, Journal of medicinal chemistry.

[14]  L. Schmidt,et al.  The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants , 2004, Oncogene.

[15]  J. Cui.  Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications , 2007 .

[16]  S. Bellon,et al.  From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. , 2009, Anti-cancer agents in medicinal chemistry.

[17]  Sylvain Lefebvre,et al.  N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[18]  S. Knapp,et al.  Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Rex,et al.  c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations* , 2008, Journal of Biological Chemistry.

[20]  K. Rex,et al.  Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. , 2008, Journal of medicinal chemistry.

[21]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.